Lipe & Dalton Trims Position in Kenvue Inc. (NYSE:KVUE)

Lipe & Dalton trimmed its holdings in Kenvue Inc. (NYSE:KVUE) by 32.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 32,367 shares of the company’s stock after selling 15,608 shares during the period. Lipe & Dalton’s holdings in Kenvue were worth $697,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Clearstead Advisors LLC purchased a new position in Kenvue in the third quarter valued at about $25,000. Planned Solutions Inc. purchased a new position in Kenvue in the fourth quarter valued at about $27,000. AdvisorNet Financial Inc purchased a new position in Kenvue in the third quarter valued at about $28,000. Global Retirement Partners LLC purchased a new position in Kenvue in the third quarter valued at about $28,000. Finally, Venturi Wealth Management LLC purchased a new position in Kenvue in the third quarter valued at about $28,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research firms have recently commented on KVUE. JPMorgan Chase & Co. lowered their price target on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research report on Friday, February 9th. William Blair assumed coverage on shares of Kenvue in a research report on Wednesday, April 3rd. They issued a “market perform” rating on the stock. The Goldman Sachs Group assumed coverage on shares of Kenvue in a research report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price on the stock. Royal Bank of Canada decreased their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research report on Friday, February 9th. Finally, Sanford C. Bernstein assumed coverage on shares of Kenvue in a research report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price on the stock. One analyst has rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $24.85.

Kenvue Stock Performance

Shares of Kenvue stock traded down $0.02 on Tuesday, hitting $19.11. The company had a trading volume of 20,219,873 shares, compared to its average volume of 16,870,912. The business has a 50-day simple moving average of $19.88 and a 200-day simple moving average of $20.18. The company has a current ratio of 1.12, a quick ratio of 0.78 and a debt-to-equity ratio of 0.69. Kenvue Inc. has a 52 week low of $17.82 and a 52 week high of $27.80.

Kenvue (NYSE:KVUE) last released its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business had revenue of $3.67 billion during the quarter, compared to analyst estimates of $3.78 billion. The firm’s quarterly revenue was down 2.7% on a year-over-year basis. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.17 EPS for the current year.

Kenvue Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, February 28th. Stockholders of record on Wednesday, February 14th were paid a dividend of $0.20 per share. The ex-dividend date was Tuesday, February 13th. This represents a $0.80 annualized dividend and a dividend yield of 4.19%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.